Vertex Pharmaceuticals Inc / Ma
—- Market cap
- —
- Debt
- —
- Cash
- −$5.08B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VRTX stock price vs WHR: inconclusive — current versus $95.30 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WHR's multiple
Implied fair value · at VRTX's multiple
Needs VRTX P/E.
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 26% equity / 74% debt · EV / Revenue 0.52x · EV proxy / EBITDA proxy 6.93x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
WHIRLPOOL CORP /DE/ · implied price per share
Bear
-$46.25
Base
-$39.05
Bull
-$26.28
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
VRTX vs AMGN
Gilead Sciences, Inc.
VRTX vs GILD
BIOGEN INC.
VRTX vs BIIB
Moderna, Inc.
VRTX vs MRNA
Illumina, Inc.
VRTX vs ILMN
BEST BUY CO INC
VRTX vs BBY
HOME DEPOT, INC.
VRTX vs HD
GENERAL ELECTRIC CO
VRTX vs GE
HELEN OF TROY LTD
VRTX vs HELE
NEWELL BRANDS INC.
VRTX vs NWL
Spectrum Brands Holdings, Inc.
VRTX vs SPB
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe VRTX’s premium growth and margin profile will continue to justify a much higher valuation than WHR’s, then hold or accumulate selectively; otherwise, reduce exposure because WHR-implied valuation and DCF range both sit far below the current price.
VRTX’s current price of $477.10 is far above WHR-implied price of $101.50, implying -78.7% downside under the P/E-based comparison. The gap is driven by VRTX’s much higher profitability and premium valuation multiples versus WHR, but the provided valuation ranges still place VRTX well above WHR-implied result.
Supporting Metrics